Igm Biosciences Inc (IGMS) Stock Price, Quote & News

Company Profile

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 965 7873

Website: igmbio.com

Address:

325 East Middlefield Road, Mountain View, United States

sumon89 Jul. 30 at 4:31 PM

$IGMS when will the deal be concluded!?

0 · Reply

NVDAMillionaire Jul. 28 at 10:57 PM

$IGMS Really good write-up that perfectly summarizes IGMS's present situation. So if you want to bring your IGMS knowledge up to date or just discover IGMS, this is required reading. https://beyondspx.com/article/igm-biosciences-a-strategic-pivot-culminates-in-acquisition-valuing-cash-and-contingent-upside-igms

0 · Reply

Candy_Wife Jul. 16 at 11:07 PM

$IGMS Did the reverse split already happen? Can't find anything about it online.

0 · Reply

sumon89 Jul. 10 at 8:30 AM

$IGMS 1.so we will lose ownership of the shares we have on this stock ? 2. the share holders are obligated to agree with the price or cand they keep the shares of igms till they become shares of the new company? Cand anyone help me understand!?

0 · Reply

SumDay1Day Jul. 1 at 8:04 PM

$IGMS What do we have here? I will toss in for 1000 shares to keep an eye on it.

0 · Reply

prismmarketview Jul. 1 at 3:25 PM

$IGMS Biotech M&A Alert: IGM Biosciences (NASDAQ: $IGMS) is being acquired by Concentra Biosciences in a cash + CVR deal that could unlock even more value for shareholders. Stock is up 18% as the market reacts. Deal expected to close by August!

0 · Reply

Blackcoupe369 Jul. 1 at 2:02 PM

$IGMS looks like she has more

0 · Reply

kebrik Jul. 1 at 1:55 PM

Today's movers: $IGMS, $WETO, $LIXT, $GPUS, and $ARBK

0 · Reply

Crapmaster2000 Jul. 1 at 1:39 PM

$IGMS 1.24 is not what I was hoping for on this deal, I was looking for at least 2.00/

0 · Reply

DARKP00L Jul. 1 at 1:33 PM

$IGMS 09:25 on Jul. 01 2025 IGM Biosciences shares are trading higher after the company announced it will be acquired by Concentra Biosciences for $1.247 per share. #tradeideas

0 · Reply

IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right

Jan 9, 2025, 2:27 PM EST - 7 months ago

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

Jan 9, 2025, 1:00 PM EST - 7 months ago

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

Nov 8, 2024, 7:00 AM EST - 9 months ago

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 7:00 AM EST - 9 months ago

IGM Biosciences to Present at Three Upcoming Investor Conferences

Oct 1, 2024, 11:41 AM EDT - 10 months ago

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

Oct 1, 2024, 11:40 AM EDT - 10 months ago

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

Oct 1, 2024, 8:00 AM EDT - 10 months ago

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

Oct 1, 2024, 7:54 AM EDT - 10 months ago

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Sep 30, 2024, 4:01 PM EDT - 10 months ago

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

Sep 10, 2024, 4:05 PM EDT - 11 months ago

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 14, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Jefferies Healthcare Conference

May 8, 2024, 4:10 PM EDT - 1 year ago

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

Apr 17, 2024, 8:30 AM EDT - 1 year ago

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Apr 10, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Mar 7, 2024, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 12, 2024, 3:09 PM EST - 1 year ago

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Feb 1, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 6, 2023, 2:44 AM EST - 1 year ago

Medivir to present at the Carlsquare Equity Research Investor Day

Dec 5, 2023, 4:01 PM EST - 1 year ago

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Dec 1, 2023, 5:32 AM EST - 1 year ago

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Nov 27, 2023, 3:52 AM EST - 1 year ago

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Nov 22, 2023, 2:46 AM EST - 1 year ago

Medivir to present at the Redeye Life Science Day

Nov 21, 2023, 2:48 AM EST - 1 year ago

Medivir to present at the Erik Penser Bank Company Event

Nov 13, 2023, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Third Quarter 2023 Financial Results

Nov 13, 2023, 3:49 AM EST - 1 year ago

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Nov 7, 2023, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at Two Upcoming Investor Conferences

Oct 25, 2023, 2:46 AM EDT - 1 year ago

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Oct 23, 2023, 2:48 AM EDT - 1 year ago

Nomination Committee of Medivir appointed

Oct 20, 2023, 9:29 AM EDT - 1 year ago

Change in Medivir's Board of Directors

Oct 5, 2023, 7:29 AM EDT - 1 year ago

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

Oct 3, 2023, 4:05 PM EDT - 1 year ago

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.

Sep 11, 2023, 5:41 AM EDT - 2 years ago

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Sep 7, 2023, 3:46 AM EDT - 2 years ago

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Sep 6, 2023, 7:00 AM EDT - 2 years ago

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 4, 2023, 2:52 AM EDT - 2 years ago

Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Sep 1, 2023, 3:20 AM EDT - 2 years ago

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Aug 14, 2023, 3:03 AM EDT - 2 years ago

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Aug 7, 2023, 2:46 AM EDT - 2 years ago

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Aug 3, 2023, 4:10 PM EDT - 2 years ago

IGM Biosciences Announces Second Quarter 2023 Financial Results

Jul 3, 2023, 4:01 PM EDT - 2 years ago

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 22, 2023, 7:58 AM EDT - 2 years ago

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

Jun 21, 2023, 5:17 PM EDT - 2 years ago

IGM Announces Proposed Public Offering and Concurrent Private Placement

Jun 19, 2023, 4:12 AM EDT - 2 years ago

Medivir's patent application for fostrox approved in China

sumon89 Jul. 30 at 4:31 PM

$IGMS when will the deal be concluded!?

0 · Reply

NVDAMillionaire Jul. 28 at 10:57 PM

0 · Reply

Candy_Wife Jul. 16 at 11:07 PM

$IGMS Did the reverse split already happen? Can't find anything about it online.

0 · Reply

sumon89 Jul. 10 at 8:30 AM

0 · Reply

SumDay1Day Jul. 1 at 8:04 PM

$IGMS What do we have here? I will toss in for 1000 shares to keep an eye on it.

0 · Reply

prismmarketview Jul. 1 at 3:25 PM

0 · Reply

Blackcoupe369 Jul. 1 at 2:02 PM

$IGMS looks like she has more

0 · Reply

kebrik Jul. 1 at 1:55 PM

Today's movers: $IGMS, $WETO, $LIXT, $GPUS, and $ARBK

0 · Reply

Crapmaster2000 Jul. 1 at 1:39 PM

$IGMS 1.24 is not what I was hoping for on this deal, I was looking for at least 2.00/

0 · Reply

DARKP00L Jul. 1 at 1:33 PM

$IGMS 09:25 on Jul. 01 2025 IGM Biosciences shares are trading higher after the company announced it will be acquired by Concentra Biosciences for $1.247 per share. #tradeideas

0 · Reply

Stock_Catcher Jul. 1 at 1:33 PM

$IGMS technical set up

0 · Reply

DARKP00L Jul. 1 at 1:25 PM

$IGMS 09:25 on Jul. 01 2025 IGM Biosciences shares are trading higher after the company announced it will be acquired by Concentra Biosciences for $1.247 per share. #tradeideas

0 · Reply

patb99 Jul. 1 at 1:03 PM

$IGMS wait the drop

0 · Reply

ret0258 Jul. 1 at 1:02 PM

$IGMS 👀👀

0 · Reply

Crapmaster2000 Jun. 30 at 6:49 PM

$IGMS

0 · Reply

SmartContent Jun. 2 at 8:30 AM

$IGMS halted its lead autoimmunity programs after weak trial results and cut over 70% of its workforce, but it still holds $184M in cash vs. a $76M market cap, giving it significant optionality to reboot its oncology pipeline. The market is discounting the firm below cash value, making this a deep-value biotech play with high risk but huge upside if it redeploys capital effectively.

0 · Reply

scrit May. 29 at 5:21 PM

$IGMS why this volume spike?

0 · Reply

scrit May. 28 at 3:23 PM

$IGMS maybe I’m an idiot buying 40.000 shares, but I smell a buyout. Market cap well below cash, we just need a powerful company to take over. I hope I’m not gambling too much…🙈

0 · Reply

JB_Research May. 27 at 8:25 PM

$IGMS Straight from their latest 10-Q: " After the termination of the Sanofi Agreement, we are not currently developing any product candidates..." "Our strategic alternatives focus on our potential internal research and development opportunities, a merger, sale, other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of our assets ... The market capitalization of our company is below current cash value and investments. Consequently, any potential counterparty may choose not to spend the additional resources necessary to continue developing our product candidates and may attribute little or no value..." https://investor.igmbio.com/node/10721/html

1 · Reply

Ali100_A May. 10 at 12:27 AM

$IGMS Is it known why Sanofi axed the entire IgM deal? Is it because IgM are too complicated to express and the fact that they are massive in size being 5 times the size of a IgG antibody.

0 · Reply

EquityInvest May. 5 at 5:07 AM

$IGMS heard that they will be filing for bankruptcy soon it was only a matter of time ha ha

0 · Reply

ret0258 Apr. 22 at 6:13 PM

$IGMS

0 · Reply

Market Cap	78.75M
Revenue (ttm)	2.68M
Net Income (ttm)	-195.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,305.97%
Debt to Equity Ratio	0.00

Volume	487,300
Avg Vol	706,446
Day's Range	N/A - N/A
Shares Out	60.12M
Stochastic %K	75%
Beta	0.60
Analysts	Hold
Price Target	$1.41